Inhibition of SYK could ameliorate the inflammation and steatosis of NAFLD by reducing the activation of macrophages and the production of CCl2, IL-6 and TNF-α [37]. This evidence concerns the gene CCL2 and metabolic dysfunction-associated steatotic liver disease.